Development of CAR T cells designed to improve antitumor efficacy and safety
- 1 October 2017
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 178, 83-91
Abstract
No abstract availableKeywords
This publication has 131 references indexed in Scilit:
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor EnvironmentMolecular Therapy, 2011
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4Journal of Biological Chemistry, 2010
- An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive ImmunotherapyMolecular Therapy, 2010
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyLeukemia, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7Molecular Therapy, 2009